AUSTIN, Texas, June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific innovations in cfDNA testing at the American Transplant Congress' (ATC) 2021 Virtual Connect, taking place June 4-9, 2021.
Search / 7 results found Showing: 7 of 7
AUSTIN, Texas, April 22, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and a global leader in cell-free DNA testing, receives pathway to future coverage for the Prospera donor-derived, cell-free DNA (dd-cfDNA) test to determine transplant rejection status in multiple organs.
ATLANTA (AP) — Thousands of absentee ballots get rejected in every presidential election. This year, that problem could be much worse and pote…
When Patrick Mannion heard about the Michigan woman denied a heart transplant because she couldn't afford the anti-rejection drugs, he knew wh…
FORT WORTH, Texas (AP) — The Texas Department of Motor Vehicles rejected more than 2,000 proposed personalized license plates last year.
Throughout Lucille O’Neal’s life, she has encountered things many people can relate to — poverty, rejection, abuse and addiction.